ʻO ka PCR Fluorescence
-
Mycobacterium Tuberculosis Isoniazid Resistance Mutation
He kūpono kēia kit no ka ʻike qualitative o nā pae hoʻololi nui i nā laʻana sputum kanaka i hōʻiliʻili ʻia mai nā maʻi maʻi maʻi Tubercle bacillus e alakaʻi i ka mycobacterium tuberculosis isoniazid resistance: InhA promoter region -15C>T, -8T>A, -8T>C;ʻĀpana hoʻolaha AhpC -12C>T, -6G>A;homozygous mutation o KatG 315 codon 315G>A, 315G>C .
-
Staphylococcus Aureus a me ka Methicillin-Resistant Staphylococcus Aureus
Hoʻohana ʻia kēia pahu no ka ʻike qualitative o staphylococcus aureus a me nā methicillin-resistant staphylococcus aureus nucleic acids i loko o nā laʻana sputum kanaka, nasal swab samples a me nā ʻili a me nā ʻiʻo palupalu nā maʻi maʻi i vitro.
-
Zika Virus
Hoʻohana ʻia kēia pahu e ʻike pono i ka Zika virus nucleic acid i loko o nā laʻana serum o nā maʻi i manaʻo ʻia he maʻi Zika virus in vitro.
-
Kāne Leukocyte Antigen B27 Nucleic Acid Detection Kit
Hoʻohana ʻia kēia pahu no ka ʻike qualitative o ka DNA i nā subtypes antigen leukocyte kanaka HLA-B*2702, HLA-B*2704 a me HLA-B*2705.
-
15 Nā ʻano o ke kanaka Papillomavirus E6/E7 Gene mRNA
Kuhi ʻia kēia pahu i ka ʻike kūpono o 15 mau kiʻekiʻe kiʻekiʻe o ka papillomavirus kanaka (HPV) E6/E7 gene mRNA hōʻike pae i loko o nā cell exfoliated o ka pūpū wahine.
-
Human Papillomavirus (28 ʻano) Genotyping
Hoʻohana ʻia kēia pahu no ka ʻike qualitative a me ka genotyping o ka nucleic acid o 28 mau ʻano o ka papillomavirus kanaka (HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52 , 53, 54, 56, 58, 59, 61, 66, 68, 73, 81, 82, 83) i loko o ka mimi kāne / wahine a me nā pūnaewele exfoliated cervical cervical, e hāʻawi ana i nā mea kōkua no ka ʻike a me ka mālama ʻana i ka maʻi HPV.
-
28 Nā ʻano o ka maʻi maʻi papilloma kanaka kiʻekiʻe (16/18 paʻi) ʻakika nucleic
He kūpono kēia pahu no ka ʻike in vitro qualitative o 28 ʻano o nā maʻi papilloma kanaka (HPV) (HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 73, 81, 82, 83) ʻakika nucleic i loko o ka mimi kāne / wahine a me nā pūpū exfoliated cervical wahine.Hiki ke paʻi ʻia ka HPV 16/18, ʻaʻole hiki ke paʻi piha ʻia nā ʻano i koe, e hāʻawi ana i mea kōkua no ka ʻike a me ka mālama ʻana i ka maʻi HPV.
-
ʻO Enterococcus kū'ē iā Vancomycin a me Gene kū'ē i ka lāʻau
Hoʻohana ʻia kēia kit no ka ʻike qualitative o vancomycin-resistant enterococcus (VRE) a me kāna mau genes kūʻē i ka lāʻau VanA a me VanB i loko o ka sputum kanaka, koko, mimi a i ʻole nā kolone maʻemaʻe.
-
Kanaka Methylated NDRG4/SEPT9/SFRP2/BMP3/SDC2 Gene
Hoʻolālā ʻia ka pahu no ka ʻike in vitro qualitative o nā genes methylated NDRG4/SEPT9/SFRP2/BMP3/SDC2 i loko o nā pūnaewele exfoliated intestinal i loko o nā mea hoʻohālike o ke kanaka.
-
ʻO ke kanaka CYP2C9 a me VKORC1 Gene Polymorphism
Pili kēia kit i ka in vitro qualitative detection of polymorphism of CYP2C9*3 (rs1057910, 1075A>C) a me VKORC1 (rs9923231, -1639G>A) i loko o ka genomic DNA o ke kanaka holookoa koko samples.
-
Kanaka CYP2C19 Gene Polymorphism
Hoʻohana ʻia kēia kit no ka ʻike in vitro qualitative o ka polymorphism o CYP2C19 genes CYP2C19*2 (rs4244285, c.681G>A), CYP2C19*3 (rs4986893, c.636G>A), CYP2C19*248 (rs4244285, c.681G>A), CYP2C19*3 (rs4986893, c.636G>A), CYP2C19*248 (rs408) >T) i loko o ka DNA genomic o nā laʻana koko holoʻokoʻa kanaka.
-
Staphylococcus Aureus a me ka Methicillin-Resistant Staphylococcus Aureus Nucleic Acid
Hoʻohana ʻia kēia pahu no ka ʻike qualitative o staphylococcus aureus a me nā methicillin-resistant staphylococcus aureus nucleic acids i loko o nā laʻana sputum kanaka, nā ʻili a me nā ʻiʻo palupalu nā maʻi maʻi, a me nā laʻana koko holoʻokoʻa in vitro.
